Citations

Clear

65 citation(s) found for "Karon, M".

Longitudinal Changes in Left Ventricular Stiffness
Redfield, Margaret M. , Melenovský, Vojtěch , Kane, Garvan C. , Karon, Barry L., Jacobsen, Steven J. , Rodeheffer, Richard J. , Borlaug, Barry A. , Melenovský, Vojtěch

Mayo Clinic

Circulation: Heart Failure | June 29, 2013 | Volume: 6 | Issue: 5 | Pages: 944-952

10.1161/circheartfailure.113.000383 | PMID 23811963 Get It

Background— Cross-sectional studies suggest that left ventricular (LV) and arterial elastance (stiffness) increase with age, but data examining longitudinal changes within human subjects are lacking. In addition, it remains unknown whether age-related LV stiffening is merely a reaction to arterial stiffening or caused by other processes. Methods and Results— Comprehensive echo-Doppler cardiography was performed in 1402 subjects participating in a randomly selected community-based study at 2 examinations separated by 4 years. From this population, 788 subjects had adequate paired data to determine LV end-systolic elastance (Ees), end-diastolic elastance (Eed), and effective arterial elastance. Throughout 4 years, blood pressure, arterial elastance, and LV mass decreased, coupled with significantly greater use of antihypertensive medications. However, despite reductions in arterial load, Ees increased by 14% (2.10±0.67–2.26±0.70 mm Hg/mL; P <0.0001) and Eed increased by 8% (0.13±0.03–0.14±0.04 mm Hg/mL; P <0.0001). Increases in Eed were greater in women than men, whereas Ees changes were similar. Age-related increases in Ees and Eed were correlated with changes in body weight, but were similar in subjects with or without cardiovascular disease. Changes in Ees were correlated with Eed ( r =0.5; P <0.0001), but not with other measures of contractility, indicating that the increase in Ees was reflective of passive stiffening rather than enhanced systolic function. Conclusions— Despite reductions in arterial load with medical therapy, LV systolic and diastolic stiffness increase over time in humans, particularly in women. In addition to blood pressure control, therapies targeting load-independent ventricular stiffening may be effective to treat and prevent age-associated cardiovascular diseases, such as heart failure.
Brief Report: Rheumatoid Arthritis Is Associated With Left Ventricular Concentric Remodeling: Results of a Population‐Based Cross‐Sectional Study
Davis, John M. , Crowson, Cynthia S. , Roger, Véronique L. , Karon, Barry L., Borgeson, Daniel D., Therneau, Terry M. , Matteson, Eric L. , Rodeheffer, Richard J. , Gabriel, Sherine E., Myasoedova, Elena , Davis, John M

Mayo Clinic

Arthritis & Rheumatism | April 1, 2013 | Volume: 65 | Issue: 7 | Pages: 1713-1718

10.1002/art.37949 | PMID 23553738 Get It

ObjectiveTo study left ventricular (LV) geometry in patients with rheumatoid arthritis (RA) and no history of heart failure compared with that in subjects with neither RA nor a history of heart failure, and to determine the impact of RA on LV remodeling.MethodsA cross‐sectional, community‐based study was conducted among adult (age ≥50 years) patients with RA and age‐ and sex‐matched subjects with neither RA nor a history of heart failure. All participants underwent standard 2‐dimensional Doppler echocardiography. LV geometry was classified into the following 4 categories based on relative wall thickness and sex‐specific cutoffs for the LV mass index: concentric remodeling, concentric hypertrophy, eccentric hypertrophy, or normal geometry.ResultsAmong 200 patients with RA and 600 age‐ and sex‐matched subjects without RA, the mean age was 65 years, and 74% of the individuals in both cohorts were female. Compared with subjects without RA, patients with RA were significantly more likely to have abnormal LV geometry (odds ratio [OR] 1.44, 95% confidence interval [95% CI] 1.03–2.00), even after adjusting for cardiovascular risk factors and comorbidities. Among subjects with abnormal LV geometry, the odds of concentric LV remodeling were significantly increased in patients with RA (OR 4.73, 95% CI 2.85–7.83). In linear regression analyses, the LV mass index appeared to be lower in patients with RA who were currently receiving corticosteroids (β ± SE −0.082 ± 0.027, P = 0.002), even after adjusting for cardiovascular risk factors and comorbidities.ConclusionRA was strongly associated with abnormal LV remodeling (particularly concentric LV remodeling) among RA patients without heart failure. This association remained significant after adjustment for cardiovascular risk factors and comorbidities. RA disease–related factors may promote changes in LV geometry. The biologic mechanisms underlying LV remodeling warrant further investigation.
Accuracy of Neonatal Transcutaneous Bilirubin Measurement in the Outpatient Setting
Wickremasinghe, Andrea C. , Karon, Brad S. , Cook, Walter J.

Mayo Clinic

Clinical Pediatrics | October 19, 2011 | Volume: 50 | Issue: 12 | Pages: 1144-1149

10.1177/0009922811417292 | PMID 22013149 Get It

Objective. To evaluate the effectiveness of transcutaneous bilirubin (TcB) measurement in predicting risk for neonatal hyperbilirubinemia in outpatients. Design. Subjects were infants ≤8 days old seen in an outpatient clinic. Infants discharged with high-risk (HR) or high-intermediate risk (HIR) total serum bilirubin (TSB) values and jaundiced infants were recruited. TSB and TcB (BiliChek) levels were plotted on an hour-specific nomogram to determine risk for hyperbilirubinemia. Results. A total of 79 infants provided 87 sets of TcB and TsB values. Mean bias and standard deviation between TcB and TsB was 1.5 ± 2.1 mg/dL for outpatients, compared with 2.7 ± 1.3 mg/dL for inpatients. The sensitivity and specificity of HR or HIR TcB for predicting an HR or HIR TSB were 87% and 58%, respectively. Of 9 infants readmitted for phototherapy, 1 had a low-risk TcB and high-risk TSB. Conclusions. TcB screening in the outpatient environment may not be safe and efficient.
In Reply
Karon, Brad S. , Boyd, James C. , Klee, George G.

Mayo Clinic

Clinical Chemistry | July 22, 2010 | Volume: 56 | Issue: 9 | Pages: 1506-1506

10.1373/clinchem.2010.152033 Get It

Glucose Meter Performance Criteria for Tight Glycemic Control Estimated by Simulation Modeling
Karon, Brad S. , Boyd, James C. , Klee, George G.

Mayo Clinic

Clinical Chemistry | June 16, 2010 | Volume: 56 | Issue: 7 | Pages: 1091-1097

10.1373/clinchem.2010.145367 | PMID 20511447 Get It

AbstractBackground: Glucose meter analytical performance criteria required for safe and effective management of patients on tight glycemic control (TGC) are not currently defined. We used simulation modeling to relate glucose meter performance characteristics to insulin dosing errors during TGC.Methods: We used 29 920 glucose values from patients on TGC at 1 institution to represent the expected distribution of glucose values during TGC, and we used 2 different simulation models to relate glucose meter analytical performance to insulin dosing error using these 29 920 initial glucose values and assuming 10%, 15%, or 20% total allowable error (TEa) criteria.Results: One-category insulin dosing errors were common under all error conditions. Two-category insulin dosing errors occurred more frequently when either 20% or 15% TEa was assumed compared with 10% total error. Dosing errors of 3 or more categories, those most likely to result in hypoglycemia and thus patient harm, occurred infrequently under all error conditions with the exception of 20% TEa.Conclusions: Glucose meter technologies that operate within a 15% total allowable error tolerance are unlikely to produce large (≥3-category) insulin dosing errors during TGC. Increasing performance to 10% TEa should reduce the frequency of 2-category insulin dosing errors, although additional studies are necessary to determine the clinical impact of such errors during TGC. Current criteria that allow 20% total allowable error in glucose meters may not be optimal for patient management during TGC.
Accuracy of Whole Blood Glucose Measurement When Venous Catheter Blood Samples Are Used on Glucose Meters
Karon, Brad S. , Koch, Christopher D. , Wockenfus, Amy M., Brown, Julie K.

Mayo Clinic

Diabetes Technology & Therapeutics | December 14, 2009 | Volume: 11 | Issue: 12 | Pages: 819-825

10.1089/dia.2009.0074 | PMID 20001684 Get It

Background: Previous studies have found positive bias and frequent outliers when central venous catheter (CVC) whole blood is used to dose glucose meters. We designed a study to determine whether positive bias and outliers with CVC whole blood glucose samples are due to exogenous glucose contamination of CVC samples, inherent bias and imprecision of glucose meters, or properties of CVC whole blood that interfere with the function of some glucose meters. Methods: We studied the relationship between venous whole blood and venous plasma glucose drawn by venipuncture to CVC whole blood and CVC plasma glucose in 50 hospitalized patients. In 27 patients whole blood glucose was measured on both the Accu-Chek ® Inform (Roche Diagnostics, Indianapolis, IN) and StatStrip™ (Nova Biomedical, Waltham, MA). Results: By comparing CVC plasma to venous plasma glucose, we determined that contamination of CVC samples with exogenous glucose was uncommon. On the Inform meter outliers were approximately twice as common with CVC whole blood compared to venous whole blood. In 27 patients who had CVC whole blood analyzed by both Inform and StatStrip, outliers occurred approximately twice as often on the Inform compared to the StatStrip. Accounting for CVC samples contaminated with exogenous glucose, outliers on the StatStrip did not occur significantly more often using CVC whole blood compared to venous whole blood. Conclusions: Properties unique to CVC whole blood differentially affect glucose meter bias and imprecision. Device selection is critical in practices that wish to use CVC whole blood to monitor glucose concentration in hospitalized patients.
Comparison of Three Whole Blood Creatinine Methods for Estimation of Glomerular Filtration Rate Before Radiographic Contrast Administration
Korpi‐Steiner, Nichole , Williamson, Eric E. , Karon, Brad S.

Mayo Clinic

American Journal of Clinical Pathology | November 19, 2009 | Volume: 132 | Issue: 6 | Pages: 920-926

10.1309/ajcpte5fey0vcgoz | PMID 19926585 Get It

Abstract We compared the clinical concordance of estimated glomerular filtration rate (eGFR) based on 3 whole blood creatinine assays with the eGFR calculated from a reference plasma creatinine assay. Whole blood creatinine on the Radiometer ABL800 FLEX (Radiometer A/S, Bronshoj, Denmark) demonstrated the best correlation and concordance to plasma creatinine/eGFR compared with the i-STAT (i-STAT, East Windsor, NJ) and StatSensor (Nova Biomedical, Waltham, MA). The i-STAT had better sensitivity (compared with Radiometer) but poorer specificity for prediction of plasma eGFR less than 60 mL/min/1.73 m2. The StatSensor demonstrated lower concordance of whole blood to plasma eGFR but offered a slope and an intercept offset feature that partially compensates for this effect. The optimal device for use in rapid determination of eGFR from whole blood creatinine may depend on whether it is more important in a given practice to optimize sensitivity, specificity, or overall concordance for determining plasma eGFR less than 60 mL/min/1.73 m2.
Catecholamine Interference in Enzymatic Creatinine Assays
Saenger, Amy K., Lockwood, Christina M. , Snozek, Christine L.H. , Milz, Thomas C., Karon, Brad S. , Scott, Mitchell G., Jaffe, Allan S. , Jaffe, Allan S.

Mayo Clinic

Clinical Chemistry | July 9, 2009 | Volume: 55 | Issue: 9 | Pages: 1732-1736

10.1373/clinchem.2009.127373 | PMID 19589845 Get It

Abstract Background: Enzymatic creatinine assays are routinely used in clinical laboratories to provide more accurate estimated glomerular filtration rates and to avoid a perceived lack of analytical specificity associated with picrate (Jaffe) methods. Negative interferences with the enzymatic creatinine assay, which we noted in several patients on dopamine or dobutamine, prompted our further investigation into interference of catecholamines with enzymatic methods. Methods: Spiked solutions of dopamine, dobutamine, epinephrine, and norepinephrine were added to pooled sera at catecholamine concentrations consistent with clinically relevant dosing. Creatinine was measured enzymatically on the Roche P-Modular, Ortho Clinical Diagnostics Vitros 350, and Abbott i-STAT. Jaffe methods were performed on the Roche P-Modular and Siemens Dimension RxL. In 10 patients receiving dopamine and/or dobutamine via a venous or arterial line we evaluated and compared the extent of in vivo creatinine interference in paired serum samples obtained by venipuncture and from indwelling catheters. Results: All catecholamines caused significant negative interference with the Roche enzymatic creatinine assay, most pronounced for dopamine and dobutamine. The Vitros enzymatic assay demonstrated slight negative interferences, and i-STAT enzymatic and Jaffe methods were unaffected by the presence of catecholamines. Significant (P &lt; 0.001) differences in creatinine concentrations by Roche enzymatic vs Jaffe methods were observed in venipuncture specimens compared with arterial or venous catheter specimens, suggesting dopamine and dobutamine reversibly adhere to the catheter lumen. Conclusions: Negative interferences were pronounced for Roche enzymatic results in blood samples obtained from indwelling catheters, a phenomenon not observed in peripheral draws. Physicians and laboratorians should be alert to the possibility of a falsely low creatinine result and reevaluate questionable samples using a method unaffected by catecholamines.
Comparison of Measured and Calculated Bicarbonate Values
Kumar, Vivek , Karon, Brad S.

Mayo Clinic

Clinical Chemistry | August 28, 2008 | Volume: 54 | Issue: 9 | Pages: 1586-1587

10.1373/clinchem.2008.107441 | PMID 18755915 Get It